CRWD vs PFE: Which Is the Better Buy?
Side-by-side comparison of CrowdStrike Holdings, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-09.
CrowdStrike Holdings, Inc. · Technology
$191.12
+32.7% upside to fair value
Grade B
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
CRWD has more upside to fair value
(+32.7%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CRWD |
PFE |
| Current Price |
$191.12 |
$25.22 |
| Fair Value Estimate |
$253.64 |
$25.92 |
| Upside to Fair Value |
+32.7%
|
+2.8%
|
| Market Cap |
$194.6B |
$143.7B |
| Forward P/E |
-4023.6x
|
19.2x
|
| EV / EBITDA |
570.3x
|
12.3x
|
| Price / Sales |
38.2x
|
2.3x
|
| Price / FCF |
134.0x
|
15.2x
|
| Revenue Growth YoY |
+25.6%
|
+5.4%
|
| Gross Margin |
75.0%
|
69.3%
|
| Operating Margin |
-3.9%
|
23.4%
|
| Return on Equity |
-0.6%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
0.75%
|
6.6%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
CrowdStrike Holdings, Inc. operates in the technology sector, specifically in software infrastructure, providing cybersecurity solutions. The business quality is medium due to its strong revenue growth of 25.6% in the most recent quarter and impressive earnings growth of 125.2% in the same period, indicating effective scaling and operational leverage. However, profitability metrics remain challen…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
CRWD |
PFE |
| Zone Low |
$190.23 |
$19.44 |
| Zone High |
$215.59 |
$22.03 |
| In Buy Zone? |
Yes
|
No
|